SBIR/STTR Research Award
""MULTIPLEXED DROPLET DIGITAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES FOR HIV DIAGNOSIS""
Award amount
$299,903Program and phase
SBIR · Phase IAward year
2023Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Vivid BioInnovations, PBC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Q1NZN4P95F83
- Solicitation number
- PHS-2023-1
- Topic code
- 115
Research abstract
Development of Diagnostics to Differentiate HIV Infection from Vaccine-Induced Seropositivity: The overarching goal of this program is to support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to vaccine-induced seropositivity (VISP), with high sensitivity and specificity. These next generation assays should be developed to address one or all applications/indications of HIV tests, namely: (1) laboratory based tests; ((2) point-of-care and clinical practices; and (3) self-testing. This contract aims to develop a droplet digital nucleic acid test to diagnose HIV infection.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- FIND-seq: A Novel Cell Sorting Technology to Enable Investigation of Rare Cells in Primary Human Tissues
- A Universal Platform for Ultrahigh-Throughput Biocatalyst Evolution With micro-Mass Spectrometry
- MULTIPLEXED NUCLEIC ACID SELF-TEST FOR REPRODUCIBLE AND SENSITIVE HIV DETECTION
- Single cell tri-omics: High coverage simultaneous profiling of DNA, RNA, and proteins in single cells
- Point-of-care viral load monitoring to support large-scale clinical testing of new HIV cure strategies
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- A MULTIFUNCTIONAL POINT-OF-CARE PLATFORM TO DIFFERENTIATE HIV INFECTION FROM VACCINE INDUCED SEROPOSITIVITY
- ""A MULTIFUNCTIONAL POINT-OF-CARE PLATFORM TO DIFFERENTIATE HIV INFECTION FROM VACCINE INDUCED SEROPOSITIVITY""
- ""THE EV-HIV ASSAY, A POINT-OF-CARE LATERAL FLOW IMMUNOASSAY TO ACCURATELY IDENTIFY HIV INFECTION FROM BLOOD-BASED EXTRACELLULAR VESICLES""
Research funding history
8 SBIR/STTR records share this UEI (2021–2025). Reported award amounts total $3,953,954. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services